Friday, 16 October 2026European Markets

ITERA And NOVABASE,SGPS Have A High Dividend Yield And Return On Equity In The Technology Sector.

Loading stream...

(VIANEWS) - ITERA (ITERA.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Technology sector.

Financial Asset Price Forward Dividend Yield Return on Equity
ITERA (ITERA.OL) kr11.60 2.62% 86.07%
NOVABASE,SGPS (NBA.LS) €5.30 2.26% 14.03%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. ITERA (ITERA.OL)

2.62% Forward Dividend Yield and 86.07% Return On Equity

Itera ASA, together with its subsidiaries, designs, develops, and operates digital solutions for companies and organizations in Norway, Denmark, and Slovakia. It offers data, artificial intelligence and analytics, development and architecture, test and quality assurance solutions, as well as cloud and application services. The company delivers projects and services in the strategy and consulting, customer experience, and technology and cloud transformation areas. Itera ASA was founded in 1989 and is based in Oslo, Norway.

Earnings Per Share

As for profitability, ITERA has a trailing twelve months EPS of kr0.76.

PE Ratio

ITERA has a trailing twelve months price to earnings ratio of 15.26. Meaning, the purchaser of the share is investing kr15.26 for every norwegian krone of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 86.07%.

Sales Growth

ITERA's sales growth is 11.8% for the current quarter and 12.4% for the next.

Earnings Before Interest, Taxes, Depreciation, and Amortization

ITERA's EBITDA is 1.13.

Moving Average

ITERA's worth is under its 50-day moving average of kr12.14 and way below its 200-day moving average of kr13.83.

Volume

Today's last reported volume for ITERA is 1500 which is 95.02% below its average volume of 30159.

More news about ITERA.

2. NOVABASE,SGPS (NBA.LS)

2.26% Forward Dividend Yield and 14.03% Return On Equity

Novabase S.G.P.S., S.A., through its subsidiaries, provides IT consulting and services in Portugal, Europe, Africa, the Middle East, and internationally. It operates through two segments, Next-Gen and Value Portfolio. The Next-Gen segment develops IT consulting and services to banks, insurance, capital markets, and telecommunication sectors. This segment operates under the Celfocus brand name. The Value Portfolio segment operates and develops IT consulting, staffing, and services under the Neotalent brand. This segment involves in venture capital activities. Novabase S.G.P.S., S.A. was incorporated in 1989 and is headquartered in Lisbon, Portugal.

Earnings Per Share

As for profitability, NOVABASE,SGPS has a trailing twelve months EPS of €0.25.

PE Ratio

NOVABASE,SGPS has a trailing twelve months price to earnings ratio of 21.2. Meaning, the purchaser of the share is investing €21.2 for every euro of annual earnings.

Return on Equity

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 14.03%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Jun 21, 2023, the estimated forward annual dividend rate is 0.1 and the estimated forward annual dividend yield is 2.26%.

More news about NOVABASE,SGPS.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com